Nimbus Therapeutics reported positive Phase IIb results on Wednesday for its TYK2 inhibitor, NDI-034858, in moderate-to-severe plaque psoriasis.
If you are not happy with the results below please do another search
50 search results for:
Full data presented Tuesday afternoon from the Phase III Clarity AD trial show Eisai and Biogen’s lecanemab has a favorable safety profile in patients with Alzheimer’s disease.
The number of people in Europe with undiagnosed HIV has risen as testing rates fell during the COVID-19 pandemic, threatening a global goal of ending the disease by 2030, a report said.
Britain is only marginally better prepared for another pandemic than it was for COVID-19, the former head of Britain’s vaccine taskforce said on Wednesday, criticizing how some structures that helped it emerge from the pandemic had been dismantled.
A Japanese biotech firm says it has developed the world’s first early screening test for pancreatic cancer, using the powerful noses of tiny worms.
The Centers for Disease Control and Prevention (CDC) said on Tuesday it is awarding more than $3 billion to help strengthen public health workforce and infrastructure across the United States after the COVID-19 pandemic put severe stress on them.
Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA explains how RWE evidence platforms can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.
As the FDA cracks down on accelerated approvals, Genentech, a Roche company, voluntarily withdrew its monoclonal antibody Tecentriq (atezolizumab) for a specific type of previously untreated metastatic bladder cancer.
Britain’s medicines regulator said on Tuesday that any new or worsening reactions in patients’ eyes arising from use of Sanofi’s best-selling asthma and eczema drug Dupixent should be promptly reviewed by healthcare professionals.
Bristol Myers Squibb is terminating a seven-year-old gene therapy collaboration to develop potential treatments for congestive heart failure with uniQure N.V. valued at $1 billion.